Select Medical Holdings Corp (SEM) Stock Analysis and Metrics

Select Medical Holdings

NYSE: SEM

$16.51 ▼ -0.02 (-0.12%)

At close: Jun 30, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap2.05 Mn

P/E0.00

P/S0.00

Div. Yield15.20

ROIC (Qtr)0.00

Total Debt (Qtr)1.86 Bn

Revenue Growth (1y) (Qtr)5.05

Add ratio to table…

About

Select Medical Holdings Corp operates as a provider of post acute care services in the United States. The company runs critical illness recovery hospitals rehabilitation hospitals and outpatient rehabilitation clinics. It serves patients who require specialized inpatient and outpatient therapy following acute hospital stays.

Select Medical Holdings Corp generates revenue primarily from delivering healthcare services through its three operating segments. For the year ended December 31 2025 the company recorded total revenue of five billion four hundred fifty two point eight million dollars. Approximately forty five percent of this revenue came from the critical illness recovery hospital segment twenty four percent from the rehabilitation hospital segment and twenty four percent from the outpatient rehabilitation segment. The remaining revenue includes fees from employee leasing services provided to non consolidating subsidiaries and minor amounts from other sources. Payor sources consist of Medicare commercial insurance workers compensation and private payments.

The company operates through the following segments: critical illness recovery hospital segment rehabilitation hospital segment and outpatient rehabilitation segment.

• Critical illness recovery hospital segment operates facilities designed to care for patients recovering from serious illnesses with complex medical needs. As of December 31 2025 the segment included 104 hospitals located in 28 states. Services are provided in both freestanding and hospital within a hospital settings. Patients are typically transferred from acute care hospitals and receive interdisciplinary care including nursing respiratory therapy physical therapy occupational therapy speech therapy and medical management. The segment earns revenue mainly from Medicare long term care hospital payments commercial insurers and private pay. Approximately thirty two percent of segment revenue came from Medicare in 2025.

• Rehabilitation hospital segment provides intensive inpatient rehabilitation for patients recovering from conditions such as stroke spinal cord injury brain trauma amputation and orthopedic surgery. As of December 31 2025 the segment operated 38 hospitals in 15 states. Care is delivered by multidisciplinary teams that include physicians nurses therapists psychologists and case managers. Medicare inpatient rehabilitation facility payments constitute the largest payor source with about forty five percent of segment revenue coming from Medicare in 2025. Additional revenue is generated from commercial insurers workers compensation and private payments.

• Outpatient rehabilitation segment runs clinics that deliver physical occupational and speech therapy services to patients with musculoskeletal injuries work related conditions and post operative needs. As of December 31 2025 the segment had 1 917 clinics spread across 39 states and the District of Columbia. Services are provided in medical office retail and freestanding locations. The majority of revenue comes from commercial insurers including health maintenance organizations workers compensation programs and private pay with about eighty three percent of segment revenue derived from commercial sources in 2025. Medicare Medicaid and other government programs supply the remainder.

Select Medical Holdings Corp holds a leading position in the post acute care industry as one of the largest operators of critical illness recovery hospitals rehabilitation hospitals and outpatient rehabilitation clinics in the United States. The company’s scale and geographic diversity enable it to negotiate favorable contracts with commercial insurers and to attract referral relationships with acute care hospitals. Key competitors in the inpatient rehabilitation space include Encompass Health Corporation and ScionHealth while the outpatient rehabilitation market features firms such as Athletico Physical Therapy ATI Physical Therapy U S Physical Therapy and Upstream Rehabilitation. Competitive advantages stem from the company’s integrated service platform its focus on quality outcomes and its ability to leverage centralized administrative functions to control costs.

The company serves a diverse customer base that includes patients recovering from acute illness or injury physicians who refer patients for specialized care commercial health insurers workers compensation programs Medicare and Medicaid programs and employers seeking occupational health services. While the filing does not disclose specific customer names the majority of revenue is derived from institutional payors and individual patients receiving treatment in the company’s facilities.

Investment Thesis

▲ Bull case

Select Medical Holdings’ ongoing bed expansion strategy provides a significant and underappreciated growth catalyst, with plans to add 275 more beds through multiple modalities by the end of 2027, including 209 in inpatient rehabilitation facilities and 66 in critical illness recovery hospitals. This development pipeline, highlighted by new hospital openings such as the 60-bed facility with AtlantiCare in Southern New Jersey scheduled for Q3 2026 and the 76-bed inpatient rehabilitation hospital in Jersey City planned for later in 2026, directly supports long-term revenue growth beyond the current fiscal year. The company’s focus on high-demand markets and strategic joint ventures, like the newly announced 50-bed inpatient rehabilitation hospital with Carilion Clinic in Roanoke, Virginia, demonstrates a disciplined approach to capturing organic growth in underserved regions. These investments are particularly compelling given the inpatient rehabilitation segment’s strong performance, with revenue per patient day up nearly 3% and same-store occupancy rising to 87%, indicating pricing power and operational efficiency. The proposed CMS rate increases of approximately 2.6% for inpatient rehabilitation and 2.66% for long-term acute care hospitals expected for fiscal year 2027 further bolster the margin outlook for these expansions, creating a tailwind that management did not emphasize during the earnings call but which could significantly enhance profitability as new beds come online.
The company’s ongoing market consolidation and optimization efforts in the outpatient rehabilitation segment represent a hidden catalyst for margin improvement that was not fully articulated in prepared remarks but emerged during the Q&A. CEO Mullen explicitly stated that Select Medical is “going through an exercise where we are looking at each of those markets, and we will consolidate certain markets where we see a path forward and where we can go from a one-PT clinic to potentially two or three PT clinics and get more productivity.” This strategy, already evidenced by the exit from the Oregon market (which incurred approximately $1 million in Q1 costs), aims to eliminate underperforming locations while increasing density and utilization in stronger markets. With outpatient revenue growing over 4% and patient visits increasing above 4%, the segment shows underlying demand resilience. By consolidating low-volume clinics into higher-productivity multi-clinic hubs, the company can achieve economies of scale in staffing, equipment, and administrative overhead, thereby reversing the margin decline seen in Q1 (adjusted EBITDA margin down to 6.8% from 7.9%). This operational restructuring, which management framed as an ongoing initiative, has the potential to meaningfully improve outpatient segment profitability over the balance of 2026 and into 2027, a development not reflected in current guidance.
Despite near-term headwinds from Medicare Advantage conversion rate declines impacting volume by approximately $13 million to $14 million year over year, Select Medical’s core inpatient rehabilitation business continues to demonstrate fundamental strength, with adjusted EBITDA up 15% to $81.1 million and margin improving to 23% from 22.9%. The critical illness recovery segment, while pressured by payer mix and volume challenges, remains a critical component of the post-acute care continuum, and the company’s exposure to it provides diversification benefits. Importantly, management noted that the proposed CMS rules for both inpatient rehabilitation and long-term acute care hospitals are expected to be finalized as proposed, with no adverse changes to the high-cost outlier threshold—a development CEO Mullen characterized as consistent with CMS’s intended policy effect. This regulatory stability reduces uncertainty and supports predictable reimbursement, enabling the company to focus on execution. Combined with a solid liquidity position ($443.5 million in revolving loan availability) and a manageable net leverage ratio of 3.75x, Select Medical has the financial flexibility to fund its expansion plans and weather near-term payer volatility, positioning it for stronger performance once the Medicare Advantage headwinds stabilize or reverse.

Select Medical Holdings’ ongoing bed expansion strategy provides a significant and underappreciated growth catalyst, with plans to add 275 more beds through multiple modalities by the end of 2027, including 209 in inpatient rehabilitation facilities and 66 in critical illness recovery hospitals. This development pipeline, highlighted by new hospital openings such as the 60-bed facility with AtlantiCare in Southern New Jersey scheduled for Q3 2026 and the 76-bed inpatient rehabilitation hospital in Jersey City planned for later in 2026, directly supports long-term revenue growth beyond the current fiscal year. The company’s focus on high-demand markets and strategic joint ventures, like the newly announced 50-bed inpatient rehabilitation hospital with Carilion Clinic in Roanoke, Virginia, demonstrates a disciplined approach to capturing organic growth in underserved regions. These investments are particularly compelling given the inpatient rehabilitation segment’s strong performance, with revenue per patient day up nearly 3% and same-store occupancy rising to 87%, indicating pricing power and operational efficiency. The proposed CMS rate increases of approximately 2.6% for inpatient rehabilitation and 2.66% for long-term acute care hospitals expected for fiscal year 2027 further bolster the margin outlook for these expansions, creating a tailwind that management did not emphasize during the earnings call but which could significantly enhance profitability as new beds come online.
The company’s ongoing market consolidation and optimization efforts in the outpatient rehabilitation segment represent a hidden catalyst for margin improvement that was not fully articulated in prepared remarks but emerged during the Q&A. CEO Mullen explicitly stated that Select Medical is “going through an exercise where we are looking at each of those markets, and we will consolidate certain markets where we see a path forward and where we can go from a one-PT clinic to potentially two or three PT clinics and get more productivity.” This strategy, already evidenced by the exit from the Oregon market (which incurred approximately $1 million in Q1 costs), aims to eliminate underperforming locations while increasing density and utilization in stronger markets. With outpatient revenue growing over 4% and patient visits increasing above 4%, the segment shows underlying demand resilience. By consolidating low-volume clinics into higher-productivity multi-clinic hubs, the company can achieve economies of scale in staffing, equipment, and administrative overhead, thereby reversing the margin decline seen in Q1 (adjusted EBITDA margin down to 6.8% from 7.9%). This operational restructuring, which management framed as an ongoing initiative, has the potential to meaningfully improve outpatient segment profitability over the balance of 2026 and into 2027, a development not reflected in current guidance.
Despite near-term headwinds from Medicare Advantage conversion rate declines impacting volume by approximately $13 million to $14 million year over year, Select Medical’s core inpatient rehabilitation business continues to demonstrate fundamental strength, with adjusted EBITDA up 15% to $81.1 million and margin improving to 23% from 22.9%. The critical illness recovery segment, while pressured by payer mix and volume challenges, remains a critical component of the post-acute care continuum, and the company’s exposure to it provides diversification benefits. Importantly, management noted that the proposed CMS rules for both inpatient rehabilitation and long-term acute care hospitals are expected to be finalized as proposed, with no adverse changes to the high-cost outlier threshold—a development CEO Mullen characterized as consistent with CMS’s intended policy effect. This regulatory stability reduces uncertainty and supports predictable reimbursement, enabling the company to focus on execution. Combined with a solid liquidity position ($443.5 million in revolving loan availability) and a manageable net leverage ratio of 3.75x, Select Medical has the financial flexibility to fund its expansion plans and weather near-term payer volatility, positioning it for stronger performance once the Medicare Advantage headwinds stabilize or reverse.

▼ Bear case

The pending take-private transaction at $16.50 per share presents a significant and underdiscussed risk to shareholder value, particularly given that multiple securities law firms—including Bleichmar Fonti & Auld LLP, Johnson Fistel, and Kaskela Law—have launched investigations into whether the board breached its fiduciary duties in approving the deal. Notably, at least one stock analyst was maintaining a price target of $19.00 per share at the time of the announcement, suggesting the offer may undervalue the company relative to market expectations. The structure of the transaction allows insiders—Robert Ortenzio, Martin Jackson, and their affiliates—to roll over their equity into the post-merger entity, while public shareholders receive only cash, creating a clear misalignment of incentives. This rollover opportunity, not extended to unaffiliated shareholders, raises concerns about whether the price reflects fair value or merely accommodates insider preferences for continued ownership. With the stockholder vote scheduled for June 26, 2026, and the merger expected to close shortly thereafter, the window for dissent or legal challenge is narrow, potentially limiting shareholders’ ability to secure a higher price despite ongoing fiduciary duty probes. The confluence of legal scrutiny, insider rollover advantages, and a price below analyst expectations constitutes a material overhang that the market may be underestimating in its assessment of near-term shareholder returns.
Select Medical’s critical illness recovery hospital segment continues to deteriorate, with adjusted EBITDA falling 15% to $73.4 million and margin declining to 11.5% from 13.6%, a trend management attributed to Medicare Advantage conversion rate declines impacting volume by approximately $13 million to $14 million year over year. Despite marginal revenue growth ($638.8 million vs. $637 million), the segment’s profitability is under persistent pressure from unfavorable payer mix and volume challenges, which management acknowledged as ongoing and difficult to forecast due to seasonality. The company’s reliance on this segment—operating 103 facilities across 28 states—exposes it to systemic risks in the long-term acute care hospital industry, including stringent admission criteria, high operating costs per patient day, and sensitivity to changes in Medicare and Medicare Advantage policies. Although CMS proposed a 2.66% rate increase for fiscal year 2027, the lack of improvement in the high-cost outlier threshold and the segment’s structural margin weakness suggest that rate updates alone will not reverse the profitability decline. Without a clear turnaround plan beyond general expectations of staying within annual guidance, the segment remains a persistent drag on consolidated earnings, and its underperformance could worsen if Medicare Advantage pressures intensify or if admissions fail to rebound.
The outpatient rehabilitation segment faces structural headwinds that are being masked by topline growth, as evidenced by declining margins despite revenue increasing over 4% and patient visits rising above 4%. Adjusted EBITDA fell to $22 million from $24.3 million, and margin dropped to 6.8% from 7.9%, indicating that the company is losing profitability even as it expands volume. While management cited scheduling optimization and market exits (such as the four clinics closed in Oregon, costing approximately $1 million in Q1) as remedies, these actions suggest underlying inefficiencies in the current model—particularly the inability to sustain profitability in certain geographic markets. The reliance on consolidating one-PT clinics into multi-clinic hubs to drive productivity assumes that scale will resolve margin issues, but there is no guarantee that this strategy will succeed, especially in competitive or low-demand areas. Furthermore, with net revenue per visit flat year over year at $102, the segment lacks pricing power, making it vulnerable to wage inflation, rising rent costs, and referral volatility. Without a meaningful improvement in net revenue per visit or a significant reduction in cost per visit, the outpatient division may continue to erode segment profitability, offsetting gains from inpatient rehabilitation and critical illness recovery, and undermining the company’s ability to meet its full-year adjusted EBITDA guidance of $520 million–$540 million.

The pending take-private transaction at $16.50 per share presents a significant and underdiscussed risk to shareholder value, particularly given that multiple securities law firms—including Bleichmar Fonti & Auld LLP, Johnson Fistel, and Kaskela Law—have launched investigations into whether the board breached its fiduciary duties in approving the deal. Notably, at least one stock analyst was maintaining a price target of $19.00 per share at the time of the announcement, suggesting the offer may undervalue the company relative to market expectations. The structure of the transaction allows insiders—Robert Ortenzio, Martin Jackson, and their affiliates—to roll over their equity into the post-merger entity, while public shareholders receive only cash, creating a clear misalignment of incentives. This rollover opportunity, not extended to unaffiliated shareholders, raises concerns about whether the price reflects fair value or merely accommodates insider preferences for continued ownership. With the stockholder vote scheduled for June 26, 2026, and the merger expected to close shortly thereafter, the window for dissent or legal challenge is narrow, potentially limiting shareholders’ ability to secure a higher price despite ongoing fiduciary duty probes. The confluence of legal scrutiny, insider rollover advantages, and a price below analyst expectations constitutes a material overhang that the market may be underestimating in its assessment of near-term shareholder returns.
Select Medical’s critical illness recovery hospital segment continues to deteriorate, with adjusted EBITDA falling 15% to $73.4 million and margin declining to 11.5% from 13.6%, a trend management attributed to Medicare Advantage conversion rate declines impacting volume by approximately $13 million to $14 million year over year. Despite marginal revenue growth ($638.8 million vs. $637 million), the segment’s profitability is under persistent pressure from unfavorable payer mix and volume challenges, which management acknowledged as ongoing and difficult to forecast due to seasonality. The company’s reliance on this segment—operating 103 facilities across 28 states—exposes it to systemic risks in the long-term acute care hospital industry, including stringent admission criteria, high operating costs per patient day, and sensitivity to changes in Medicare and Medicare Advantage policies. Although CMS proposed a 2.66% rate increase for fiscal year 2027, the lack of improvement in the high-cost outlier threshold and the segment’s structural margin weakness suggest that rate updates alone will not reverse the profitability decline. Without a clear turnaround plan beyond general expectations of staying within annual guidance, the segment remains a persistent drag on consolidated earnings, and its underperformance could worsen if Medicare Advantage pressures intensify or if admissions fail to rebound.
The outpatient rehabilitation segment faces structural headwinds that are being masked by topline growth, as evidenced by declining margins despite revenue increasing over 4% and patient visits rising above 4%. Adjusted EBITDA fell to $22 million from $24.3 million, and margin dropped to 6.8% from 7.9%, indicating that the company is losing profitability even as it expands volume. While management cited scheduling optimization and market exits (such as the four clinics closed in Oregon, costing approximately $1 million in Q1) as remedies, these actions suggest underlying inefficiencies in the current model—particularly the inability to sustain profitability in certain geographic markets. The reliance on consolidating one-PT clinics into multi-clinic hubs to drive productivity assumes that scale will resolve margin issues, but there is no guarantee that this strategy will succeed, especially in competitive or low-demand areas. Furthermore, with net revenue per visit flat year over year at $102, the segment lacks pricing power, making it vulnerable to wage inflation, rising rent costs, and referral volatility. Without a meaningful improvement in net revenue per visit or a significant reduction in cost per visit, the outpatient division may continue to erode segment profitability, offsetting gains from inpatient rehabilitation and critical illness recovery, and undermining the company’s ability to meet its full-year adjusted EBITDA guidance of $520 million–$540 million.

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password